TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Ocumension Therapeutics ( (HK:1477) ).
Ocumension Therapeutics has received authorization to initiate a phase III clinical trial for OT-802, a self-developed treatment for presbyopia, in China. This development underscores the company’s research capabilities and highlights the significant commercial potential in the underserved presbyopia treatment market in the region.
The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
More about Ocumension Therapeutics
Ocumension Therapeutics is a company incorporated in the Cayman Islands, focusing on the development of innovative ophthalmic products. The company is actively involved in the research and development of treatments for eye conditions, with a particular focus on the presbyopia treatment market in China.
Average Trading Volume: 4,836,336
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.29B
For a thorough assessment of 1477 stock, go to TipRanks’ Stock Analysis page.